# US 2017/0283347 A1 · Novel adamantane derivative compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283347 A1
- Document ID: US20170283347A1
- Status: Published application
- Kind: A1
- Application number: 15/506,972
- Filed: 2015-08-24
- Published: 2017-10-05
- Earliest claimed: 2014-08-29
- Assignees: Amorepacific Corporation
- Applicants: Amorepacific Corporation
- Inventors: Yung Hyup JOO; Song Seok SHIN; Byoung Young WOO; Heung Soo BAEK; Yong Deog HONG; Hong-Ju SHIN; Yeon Su JEONG; Jon Hwan LEE
- Web page: https://patentgrep.com/patent/US20170283347A1

## CPC

- C07C 13/615: with an adamantane ring
- A61K 8/42: Amides
- A61K 8/49: containing heterocyclic compounds
- A61K 8/4973: {with oxygen as the only hetero atom}
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/08: Antiseborrheics
- A61P 17/14: for baldness or alopecia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 7/00: Preparations for affecting hair growth
- A61Q 19/008: {Preparations for oily skin}
- C07C 15/04: Benzene
- C07C 231/02: from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
- C07C 233/57: having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C 233/58: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C 233/59: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C 233/60: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 233/63: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 265/12: having isocyanate groups bound to carbon atoms of six-membered aromatic rings
- C07D 263/56: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- C07C 2603/74: Adamantanes
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed is a novel adamantine derivative compound, an isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or a solvate thereof. Also disclosed is a method for preparing a novel adamantine derivative compound, an isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or a solvate thereof. The novel adamantane derivative compound or the like has an excellent anti-androgenic effect.

## Claims

### Claim 1

A compound represented by the following Chemical Formula 1, an isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or a solvate thereof:
wherein X is —NHCO— or —CONH—,
each of R1 and R2 is independently substituted, R1 is selected from the group consisting of hydrogen, halogen, NO2, C1-C6 alkoxy, CN, CO2Me, CO2H and NH2,
R2 is selected from the group consisting of hydrogen, C1-C6 alkoxy, C1-C6 alkyl and halogen,
or
R1 and R2 are linked to each other to form a cyclic carbon chain optionally containing a hetero atom, wherein the cyclic carbon chain is selected from the group consisting of C2-C18 cycloalkyl; C4-C18 aryl; C2-C18 heterocycloalkyl in which at least one carbon is substituted with at least one hetero atom selected from nitrogen, oxygen and sulfur; and C4-C18 heteroaryl in which at least one carbon is substituted with at least one hetero atom selected from nitrogen, oxygen and sulfur;
R3 is selected from the group consisting of hydrogen, C1-C6 alkoxy and halogen.

### Claim 2 (depends on 1)

The compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof according to claim 1, wherein R2 is selected from the group consisting of hydrogen, C1-C3 alkoxy, C1-C3 alkyl and halogen.

### Claim 3 (depends on 1)

The compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof according to claim 1, wherein R1 and R2 are linked to each other to form a carbon chain or hetero atom-containing chain selected from the group consisting of 1,3-dioxole, 1,3-thiazole, 1,3-oxazole, pyridyl and cyclobutyl.

### Claim 4 (depends on 1)

The compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof according to claim 1, wherein the halogen is chloride.

### Claim 5 (depends on 1)

The compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof according to claim 1, wherein
R1 is NO2 or CN;
R2 is hydrogen, methyl, methoxy or chloride; and
R3 is hydrogen, methoxy or chloride.

### Claim 6 (depends on 1)

The compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof according to claim 1, wherein when R3 is hydrogen and R2 is halogen, R2 is chloride.

### Claim 7 (depends on 1)

The compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof according to claim 1, which is selected from the group consisting of:
adamantan-1-carboxylic acid-(3-methyl-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(3-methoxy-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(3-chloro-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(2-chloro-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(4-cyano-3-methoxy-phenyl)amide;
adamantan-1-carboxylic acid-(4-cyano-2-chloro-phenyl)amide;
N-adamantan-1-yl-N-(4-nitro-3-methyl-phenyl)-acetamide,
N-adamantan-1-yl-N-(4-nitro-3-methoxy-phenyl)-acetamide,
N-adamantan-1-yl-N-(4-nitro-3-chloro-phenyl)-acetamide,
N-adamantan-1-yl-N-(4-nitro-2-chloro-phenyl)-acetamide,
adamantan-1-carboxylic acid benzo[1,3]dioxol-5-ylamide,
adamantan-1-carboxylic acid benzothiazol-6-ylamide;
adamantan-1-carboxylic acid (3-methoxyphenyl)amide;
adamantan-1-carboxylic acid (4-nitrophenyl)amide;
adamantan-1-carboxylic acid phenylamide;
adamantan-1-carboxylic acid (3,4-dimethoxyphenyl)amide;
adamantan-1-carboxylic acid (4-fluoro-3-methoxyphenyl)amide;
adamantan-1-carboxylic acid benzoxazol-6-ylamide;
adamantan-1-carboxylic acid (4-bromo-3-methoxyphenyl)amide;
adamantan-1-carboxylic acid quinolin-6-ylamide;
4-[(adamantan-1-carbonyl)-amino]2-methoxy-benzoic acid methylester;
adamantan-1-carboxylic acid (4-methoxyphenyl)amide;
adamantan-1-carboxylic acid (3-nitrophenyl)amide;
adamantan-1-carboxylic acid (5,6,7,8-tetrahydronaphthalen-2-yl)amide;
adamantan-1-carboxylic acid (2-methoxy-4-nitrophenyl)amide; and
4-[(adamantan-1-carbonyl)-amino]-2-methoxybenzoic acid.

### Claim 8 (depends on 1)

A method for inhibiting androgen of a subject, wherein the method comprises administering an effective amount of the compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof according to claim 1 to the subject in need thereof:

### Claim 9 (depends on 8)

The method according to claim 8, wherein the compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof, which is selected from the group consisting of:
adamantan-1-carboxylic acid-(3-methyl-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(3-methoxy-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(3-chloro-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(2-chloro-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(4-cyano-3-methoxy-phenyl)amide;
adamantan-1-carboxylic acid-(4-cyano-2-chloro-phenyl)amide;
N-adamantan-1-yl-N-(4-nitro-3-methyl-phenyl)-acetamide;
N-adamantan-1-yl-N-(4-nitro-3-methoxy-phenyl)-acetamide;
N-adamantan-1-yl-N-(4-nitro-3-chloro-phenyl)-acetamide;
N-adamantan-1-yl-N-(4-nitro-2-chloro-phenyl)-acetamide;
adamantan-1-carboxylic acid benzo[1,3]dioxol-5-ylamide;
adamantan-1-carboxylic acid benzothiazol-6-ylamide;
adamantan-1-carboxylic acid (3-methoxyphenyl)amide;
adamantan-1-carboxylic acid (4-nitrophenyl)amide;
adamantan-1-carboxylic acid phenylamide;
adamantan-1-carboxylic acid (3,4-dimethoxyphenyl)amide;
adamantan-1-carboxylic acid (4-fluoro-3-methoxyphenyl)amide;
adamantan-1-carboxylic acid benzoxazol-6-ylamide;
adamantan-1-carboxylic acid (4-bromo-3-methoxyphenyl)amide;
adamantan-1-carboxylic acid quinolin-6-ylamide;
4-[(adamantan-1-carbonyl)-amino]2-methoxy-benzoic acid methylester;
adamantan-1-carboxylic acid (4-methoxyphenyl)amide;
adamantan-1-carboxylic acid (3-nitrophenyl)amide;
adamantan-1-carboxylic acid (5,6,7,8-tetrahydronaphthalen-2-yl)amide;
adamantan-1-carboxylic acid (2-methoxy-4-nitrophenyl)amide; and
4-[(adamantan-1-carbonyl)-amino]-2-methoxybenzoic acid.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof, which stimulates hair growth.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof, which inhibits sebum production.

### Claim 12 (depends on 1)

A composition comprising the compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof as defined in claim 1.

### Claim 13 (depends on 1, 12)

The composition according to claim 12, which comprises the compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof as defined in claim 1, in an amount of 0.01 wt %-20 wt % based on the total weight of the composition.

### Claim 14 (depends on 12)

The composition according to claim 12, wherein the compound, isomer
thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof, which is selected from the group consisting of:
adamantan-1-carboxylic acid-(3-methyl-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(3-methoxy-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(3-chloro-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(2-chloro-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(4-cyano-3-methoxy-phenyl)amide;
adamantan-1-carboxylic acid-(4-cyano-2-chloro-phenyl)amide;
N-adamantan-1-yl-N-(4-nitro-3-methyl-phenyl)-acetamide;
N-adamantan-1-yl-N-(4-nitro-3-methoxy-phenyl)-acetamide;
N-adamantan-1-yl-N-(4-nitro-3-chloro-phenyl)-acetamide;
N-adamantan-1-yl-N-(4-nitro-2-chloro-phenyl)-acetamide;
adamantan-1-carboxylic acid benzo[1,3]dioxol-5-ylamide;
adamantan-1-carboxylic acid benzothiazol-6-ylamide;
adamantan-1-carboxylic acid (3-methoxyphenyl)amide;
adamantan-1-carboxylic acid (4-nitrophenyl)amide;
adamantan-1-carboxylic acid phenylamide;
adamantan-1-carboxylic acid (3,4-dimethoxyphenyl)amide;
adamantan-1-carboxylic acid (4-fluoro-3-methoxyphenyl)amide;
adamantan-1-carboxylic acid benzoxazol-6-ylamide;
adamantan-1-carboxylic acid (4-bromo-3-methoxyphenyl)amide;
adamantan-1-carboxylic acid quinolin-6-ylamide;
4-[(adamantan-1-carbonyl)-amino]2-methoxy-benzoic acid methylester;
adamantan-1-carboxylic acid (4-methoxyphenyl)amide;
adamantan-1-carboxylic acid (3-nitrophenyl)amide;
adamantan-1-carboxylic acid (5,6,7,8-tetrahydronaphthalen-2-yl)amide;
adamantan-1-carboxylic acid (2-methoxy-4-nitrophenyl)amide; and
4-[(adamantan-1-carbonyl)-amino]-2-methoxybenzoic acid.

### Claim 15 (depends on 12)

The composition according to claim 12, which is a skin application composition.

### Claim 16 (depends on 12)

The composition according to claim 12, which is an anti-androgenic composition.

### Claim 17 (depends on 12)

The composition according to claim 12, which is a composition for stimulating hair growth.

### Claim 18 (depends on 12)

The composition according to claim 12, which is an anti-sebum composition.

### Claim 19 (depends on 1)

A method for preparing the compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof as defined in claim 1, the method comprising: reacting a compound represented by the following Chemical Formula 2 or 3 with a benzoic acid salt derivative or phenylamine derivative in the presence of a base:

### Claim 20 (depends on 19)

The method according to claim 19, wherein the compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof, which is selected from the group consisting of:
adamantan-1-carboxylic acid-(3-methyl-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(3-methoxy-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(3-chloro-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(2-chloro-4-nitrophenyl)amide;
adamantan-1-carboxylic acid-(4-cyano-3-methoxy-phenyl)amide;
adamantan-1-carboxylic acid-(4-cyano-2-chloro-phenyl)amide;
N-adamantan-1-yl-N-(4-nitro-3-methyl-phenyl)-acetamide,
N-adamantan-1-yl-N-(4-nitro-3-methoxy-phenyl)-acetamide,
N-adamantan-1-yl-N-(4-nitro-3-chloro-phenyl)-acetamide,
N-adamantan-1-yl-N-(4-nitro-2-chloro-phenyl)-acetamide,
adamantan-1-carboxylic acid benzo[1,3]dioxol-5-ylamide,
adamantan-1-carboxylic acid benzothiazol-6-ylamide;
adamantan-1-carboxylic acid (3-methoxyphenyl)amide;
adamantan-1-carboxylic acid (4-nitrophenyl)amide;
adamantan-1-carboxylic acid phenylamide;
adamantan-1-carboxylic acid (3,4-dimethoxyphenyl)amide;
adamantan-1-carboxylic acid (4-fluoro-3-methoxyphenyl)amide;
adamantan-1-carboxylic acid benzoxazol-6-ylamide;
adamantan-1-carboxylic acid (4-bromo-3-methoxyphenyl)amide;
adamantan-1-carboxylic acid quinolin-6-ylamide;
4-[(adamantan-1-carbonyl)-amino]2-methoxy-benzoic acid methylester;
adamantan-1-carboxylic acid (4-methoxyphenyl)amide;
adamantan-1-carboxylic acid (3-nitrophenyl)amide;
adamantan-1-carboxylic acid (5,6,7,8-tetrahydronaphthalen-2-yl)amide;
adamantan-1-carboxylic acid (2-methoxy-4-nitrophenyl)amide; and
4-[(adamantan-1-carbonyl)-amino]-2-methoxybenzoic acid.
